Our Medicines
Vimy-semaglutide and Vimy-semaglutide (WT)
Two high-quality, Canadian-manufactured generic semaglutide medicines, supplied in vials.
- Status
- Both under Health Canada review
- Format
- Vial, once weekly
- References
- Ozempic® and Wegovy®
- Manufactured in
- Canada
MY Health: Reliable. Affordable. Canadian.
Prioritize your long-term health with high-quality, Canadian-manufactured medicines that are in reliable supply, accessible and affordable.
With 5 million Canadians living with type 2 diabetes1 and 10 million living with obesity,2 managing our individual and collective long-term health has never been more important. For the more than 1 million Canadians currently receiving treatment with injectable semaglutide (Ozempic® and Wegovy®),3 this health journey has already begun.
Vimy Pharma is a Canadian pharmaceutical company, built to produce an abundant supply of this World Health Organization (“W.H.O.”) essential medicine.4 In a market that has experienced shortages,5 Vimy Pharma is set up to produce an initial 10 million units per year, enough for 750,000 Canadian patients, with plans to quadruple capacity over the coming years.6
The best part: Vimy Pharma injectable semaglutide is planned at one third of the brand price,7 and it will be manufactured right here at home. A high-quality, affordable generic option will open access to the millions of Canadians who would benefit from this W.H.O. essential medicine.8 Manufacturing in Canada, to Health Canada’s rigorous standards, means skilled Canadian jobs, investment at home, greater reliable, high-quality supply, and greater pharmaceutical sovereignty.
Vimy Pharma’s injectable semaglutide products are pending Health Canada approval.

Two medicines
Generic semaglutide injectables, supplied in vials. Each references a different brand medicine.
Why vials
The most widely used format for injectable medicines, used by millions in North America for GLP-1-based medicines.
A smaller package offsets limited refrigerator capacity at wholesalers and in pharmacies.
Ubiquitous vial and component supply avoids potential bottlenecks in generic pen supply.
Looking ahead
Vimy Pharma is built to supply essential medicines, starting with semaglutide.
As we scale capacity and bring Vimy-semaglutide and Vimy-semaglutide (WT) to patients in Canada and beyond, our focus stays the same: high-quality, affordable medicines in reliable supply.
Sources and notes
- Diabetes Canada, Diabetes in Canada: Backgrounder (Toronto: Diabetes Canada, October 2024). Estimates 5,805,000 people in Canada living with diabetes in 2024 (type 1, diagnosed type 2 and undiagnosed type 2); type 1 represents 5–10% of prevalence, implying approximately 5.2–5.5 million with type 2 diabetes. https://www.diabetes.ca/what-is-diabetes/diabetes-in-canada
- Calculated by applying Obesity Canada’s reported obesity prevalence of 26.4% (BMI ≥ 30 kg/m²) to Statistics Canada’s population estimate of 41,798,407 as of July 1, 2026 (approximately 11.0 million; rounded down to 10 million). L.K. Twells, I. Janssen and J.L. Kuk, “Epidemiology of Adult Obesity,” in Canadian Adult Obesity Clinical Practice Guidelines (Obesity Canada, 2020), https://obesitycanada.ca/guidelines/epidemiology, accessed October 28, 2026; Statistics Canada, Table 17-10-0009-01, Population Estimates, Quarterly, released September 23, 2026.
- IQVIA Canada, semaglutide (Ozempic® and Wegovy®) unit sales, MAT, equivalent to more than 1 million patients treated for a full year at approximately one pen per month. See also Novo Nordisk Canada Inc., “Novo Nordisk confirms stable Ozempic® supply across Canada,” press release (Mississauga, ON, September 18, 2026).
- World Health Organization, The Selection and Use of Essential Medicines, 2025: WHO Model List of Essential Medicines, 24th List (Geneva: WHO, September 5, 2025), https://doi.org/10.2471/B09474. GLP-1 receptor agonists, including semaglutide, were added for type 2 diabetes with cardiovascular disease, chronic kidney disease or obesity.
- Health Canada, Drug Shortages in Canada: Fiscal Year 2023 to 2024 in Review (Ottawa, November 2024), identifying Ozempic® as a high-impact (Tier 3) shortage from August 2023 to February 2024 due to worldwide demand; Health Canada, “Supply of Ozempic and other GLP-1 receptor agonists: Notice” (published April 6, 2023; shortage declared resolved January 27, 2025). Manufacturer reports on Health Canada’s drug shortage database (healthproductshortages.ca) include: Ozempic® 1 mg (DIN 02471469) and 1.34 mg/mL (DIN 02471477), Novo Nordisk Canada Inc., demand increase, resolved January 17 and February 16, 2024; Semaglutide Injection 1.34 mg/mL (DINs 02567806, 02567814), Dr. Reddy’s Laboratories Ltd., disruption of manufacture, actual shortage since July 20, 2026; Apo-Semaglutide Injection 0.68 mg/mL and 1.34 mg/mL (DINs 02568020, 02568012; Report #293555), Apotex Inc., demand increase, actual shortage since September 15, 2026. Accessed October 28, 2026.
- Company estimate. Patient figure assumes approximately 13 units per patient per year (10,000,000 ÷ 750,000), consistent with one four-week pen per patient. Capacity and expansion plans are forward-looking and subject to regulatory approval, financing and operational factors.
- Company estimate, compared with an average of approximately $227 per Ozempic® pen derived from public list price with ODB. Final pricing will be set at launch and is subject to market and regulatory factors.
- A February 2026 Leger Healthcare survey estimated that more than 2 million Canadian adults are interested in taking a GLP-1 medication but are not currently doing so, with more than half saying insurance coverage or lower-cost generic options would affect their decision. N. Ireland, “3 million Canadians use GLP-1 drugs,” CBC News / The Canadian Press, March 4, 2026.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S.
Rigorous by design
A peptide testing and development program shaped by Health Canada’s standards.
Traditional assays plus advanced, orthogonal methods specific to peptides.
Completed in Q1 2026, with a data readout.
Thousands of pages of data, filed with Health Canada in May and August 2026.
Manufacturing standards
Vimy-semaglutide and Vimy-semaglutide (WT) will be manufactured in Canada to Health Canada’s rigorous standards.
Images of Steriline vial production lines to be used for Vimy-semaglutide and Vimy-semaglutide (WT) at Canada’s Critical Medicines Production Centre.
